Can BioSAXS detect ultrastructural changes of antifungal compounds in Candida albicans?–an exploratory study
The opportunistic yeast Candida albicans is the most common cause of candidiasis. With only four classes of antifungal drugs on the market, resistance is becoming a problem in the treatment of fungal infections, especially in immunocompromised patients. The development of novel antifungal drugs with...
Main Authors: | Kai Hilpert, Christoph Rumancev, Jurnorain Gani, Dominic W. P. Collis, Paula Matilde Lopez-Perez, Vasil M. Garamus, Ralf Mikut, Axel Rosenhahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1141785/full |
Similar Items
-
Rational Designed Hybrid Peptides Show up to a 6-Fold Increase in Antimicrobial Activity and Demonstrate Different Ultrastructural Changes as the Parental Peptides Measured by BioSAXS
by: Kai Hilpert, et al.
Published: (2021-12-01) -
BioSAXS–an emerging method to accelerate, enrich and de-risk antimicrobial drug development
by: Christoph Rumancev, et al.
Published: (2022-08-01) -
BioSAXS Measurements Reveal That Two Antimicrobial Peptides Induce Similar Molecular Changes in Gram-Negative and Gram-Positive Bacteria
by: Andreas von Gundlach, et al.
Published: (2019-09-01) -
Cubic Liquid Crystalline Nanostructures Involving Catalase and Curcumin: BioSAXS Study and Catalase Peroxidatic Function after Cubosomal Nanoparticle Treatment of Differentiated SH-SY5Y Cells
by: Miora Rakotoarisoa, et al.
Published: (2019-08-01) -
New data analysis for BioSAXS at the ESRF
by: Jérôme Kieffer, et al.
Published: (2022-09-01)